Association of Lp‐PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population

Ni, Jing; Gu, Hong; Hu, Wuhao; Zhou, Fang; Zhu, Xue Zhen; Wang, Ke

doi:10.1002/jbt.21999

Cited by 6 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Definitely, the present study suggested that high Lp-PLA2 mass levels could possibly be used as a biomarker for ischemic stroke since; it regarded as SR stratification mainly in Chines and general populations. [ 40 ] Findings of our study certainly revealed that statins therapy produced significant reduction in Lp-PLA2 mass levels in statins user patients compared to the nonstatin users in patients with ischemic stroke that correspond with Safarova et al ., study that revealed a significant effect of statins on the reduction of Lp-PLA2 mass levels in patients with progressive atherosclerosis. [ 41 ] On contrast, Otsuka et al .…”

Section: Discussionsupporting

confidence: 88%

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Al-Kuraishy

Al-Gareeb

Waheed

2018

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

Objectives:The objective of the study is to investigate the effects of statins on the lipoprotein-associated phospholipase A2 (Lp-PLA2) mass in patients with ischemic stroke.Materials and Methods:A total number of 59 patient ages 43–69 years with cerebral stroke compared to 39 healthy controls that matching the age and body weight. The patients were divided into 32 patients on statins therapy assigned as statins users and 27 patients, not on statins therapy assigned as nonstatins users. Anthropometric and biochemical measurements were done including lipid profile and inflammatory biomarkers.Results:Stroke patients on statins therapy showed a comparable low of Lp-PLA (29.82 ± 3.19 IU/mL) to nonstatins user stroke patients (15.58 ± 5.73 IU/mL). Lp-PLA2 mass levels were positively correlated with body mass index, blood pressure changes, total cholesterol, triglyceride, and very low-density lipoprotein and stroke risk (SR) percentage.Conclusions:Patients on statins with ischemic stroke had low levels of Lp-PLA2 mass levels compared to nonstatins user with ischemic stroke. Lp-PLA2 mass levels were higher in men than women and correlated with lipid profile and SR in patients with ischemic stroke.

show abstract

Section: Discussionsupporting

confidence: 88%

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Al-Kuraishy

Al-Gareeb

Waheed

2018

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

show abstract

“… 29 , 30 The Lp-PLA2 G994T gene polymorphism may be an independent risk factor for ischemic stroke in a Chinese population. 31 Higher levels of Lp-PLA2 in the acute phase were associated with an increased short-term risk of recurrence of vascular events. 32 Furthermore, high serum LP-PLA2 levels are associated with the incidence, severity, and recurrence of AIS, which can be used to guide clinical practice.…”

Section: Discussionmentioning

confidence: 97%

Negative correlation between early recovery and lipoprotein-associated phospholipase A2 levels after intravenous thrombolysis

Wang

Guo

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Objective Lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered a biomarker for systemic inflammation and the risk of myocardial infarction and stroke. However, little is known about the effect of acute vascular events on marker levels. The purpose of this study was to assess the potential association of early recovery with Lp-PLA2 levels in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT). Methods Forty-three consecutive AIS patients who had their first stroke and were hospitalized within 5 hours of the onset of stroke were enrolled. All patients were treated with IVT using alteplase or urokinase. Plasma Lp-PLA2 levels were measured within 24 hours after IVT. Variables that showed a significant association with Lp-PLA2 in univariate analysis were included in the multivariate ordered logistic regression model. Results Early recovery was associated with Lp-PLA2 levels after IVT, and Lp-PLA2 levels tended to decrease with increased probability of early recovery. This study is the first to report a negative correlation between early recovery and Lp-PLA2 levels after IVT. Conclusion Early recovery after IVT was negatively correlated with Lp-PLA2 A2 levels.

show abstract

“…Interestingly, inconsistent results were obtained even for the same ethnic population and disease as well. For example, a case‐control study demonstrated no significant association between the V279F mutation and ischemic stroke in a Chinese population (OR = 0.82, 95% CI: 0.44‐1.24), whereas another genetic study established an increased risk despite using the same study population and disease (OR = 2.51, 95% CI: 1.02‐5.91, P = .037) . In the case of atherosclerosis, a significant inverse association of V279F polymorphism with clinical atherosclerosis was indicated in a recent meta‐analysis (OR = 0.88, 95% CI: 0.81‐0.95, P = .0007), whereas another study did not reveal any significant associations between the V279F genotype and subclinical atherosclerosis using Mendelian randomization analyses .…”

Section: Genetic Variability and Regulation Of Expressionmentioning

confidence: 99%

Lipoprotein‐associated phospholipase A2: The story continues

Huang

Wang

Shen

2019

Medicinal Research Reviews

131

140

View full text Add to dashboard Cite

Inflammation is thought to play an important role in the pathogenesis of vascular diseases. Lipoprotein‐associated phospholipase A2 (Lp‐PLA2) mediates vascular inflammation through the regulation of lipid metabolism in blood, thus, it has been extensively investigated to identify its role in vascular inflammation‐related diseases, mainly atherosclerosis. Although darapladib, the most advanced Lp‐PLA2 inhibitor, failed to meet the primary endpoints of two large phase III trials in atherosclerosis patients cotreated with standard medical care, the research on Lp‐PLA2 has not been terminated. Novel pathogenic, epidemiologic, genetic, and crystallographic studies regarding Lp‐PLA2 have been reported recently, while novel inhibitors were identified through a fragment‐based lead discovery strategy. More strikingly, recent clinical and preclinical studies revealed that Lp‐PLA2 inhibition showed promising therapeutic effects in diabetic macular edema and Alzheimer's disease. In this review, we not only summarized the knowledge of Lp‐PLA2 established in the past decades but also emphasized new findings in recent years. We hope this review could be valuable for helping researchers acquire a much deeper insight into the nature of Lp‐PLA2, identify more potent and selective Lp‐PLA2 inhibitors, and discover the potential indications of Lp‐PLA2 inhibitors.

show abstract

Association of Lp‐PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population

Cited by 6 publications

References 25 publications

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Negative correlation between early recovery and lipoprotein-associated phospholipase A2 levels after intravenous thrombolysis

Lipoprotein‐associated phospholipase A2: The story continues

Contact Info

Product

Resources

About